Private capital returns, cautiously

Money is moving back into private markets, but it is moving like airline passengers during a storm: most people are crowding around the biggest gates. Private equity funds had raised $152 billion by March 31, 2026, up from $133 billion a year earlier, and that first-quarter total was the strongest since the first quarter of 2022. (buyoutsinsider.com) The catch is that fewer funds are actually closing. The new money is being anchored by giant names like Kohlberg Kravis Roberts, whose fourteenth flagship fund reached a $23 billion final close and helped pull the quarter’s total upward. (buyoutsinsider.com) At the same time, mergers are coming back at the top end of the market. One April 9 market roundup said the first quarter of 2026 produced $438 billion in megadeal value, with 12 transactions above $10 billion. (markets.financialcontent.com) That does not mean buyers suddenly love risk again. It means boards, lenders, and limited partners are willing to back very large transactions when the target is obvious, the manager is familiar, and the asset can be explained in one sentence. (markets.financialcontent.com) (buyoutsinsider.com) Pharmaceutical companies are one place where that caution is already turning into deals. Chemical & Engineering News reported on April 10 that large drugmakers facing patent expirations and sitting on cash have stepped up biotech acquisitions since the start of 2026. (cen.acs.org) The logic is simple: when a blockbuster drug loses patent protection, cheaper copies can eat into sales fast, so buying a smaller biotechnology company is a way to refill the medicine cabinet before shelves go empty. The recent pickup in biotech takeovers is also giving investors a rare thing they have lacked for two years: exits. (cen.acs.org) Another corner of private capital is growing by opening the door to smaller investors. The National Law Review said on April 9 that the “retailization” of private credit, meaning private loans being packaged for a wider investing public, is now drawing heavier attention from the Securities and Exchange Commission and from plaintiffs’ lawyers. (natlawreview.com) That scrutiny is aimed at a basic mismatch. Private credit loans can be hard to price and hard to sell quickly, while retail-style products are often marketed to people who expect clearer valuations, easier access, and stronger guardrails. (natlawreview.com) So the rebound is real, but it is narrow. The money is returning first to the biggest managers, the biggest takeovers, and the clearest industry stories, while the parts of private markets reaching for new investors are meeting regulators and litigators at the door. (buyoutsinsider.com) (markets.financialcontent.com) (natlawreview.com)